RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Testing THRIVE 365 for Black Sexual Minority Men (On The Daily)

Not Applicable

Completed

Conditions: Emotion Regulation
Anxiety Symptoms
Medication Adherence
Depressive Symptoms

Interventions: Behavioral: iTHRIVE 365

First Posted Date: 2022-05-17

Last Posted Date: 2024-03-27

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 34

Registration Number: NCT05376397

Locations: 🇺🇸
Devin English, Newark, New Jersey, United States

Mobile Messaging for Improved Nutrition

Not Applicable

Completed

Conditions: Diet, Healthy
Anemia

Interventions: Behavioral: Infant and young child feeding voice messaging intervention

First Posted Date: 2022-05-16

Last Posted Date: 2023-03-29

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 492

Registration Number: NCT05374837

Locations: 🇸🇳
Institut de Recherche en Santé de Surveillance Epidemiologique et de Formation, Dakar, Senegal

MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors

Not Applicable

Recruiting

Conditions: Melanoma

Interventions: Other: Assess implementation outcomes
Other: MySmartSkin enhancement
Other: Educational webpage on Skin Self-Examination

First Posted Date: 2022-05-13

Last Posted Date: 2024-07-05

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 385

Registration Number: NCT05373823

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Afferent Neurocardiac Signals, Cue Reactivity, and Cognitive Control

Not Applicable

Conditions: Binge Drinking

Interventions: Behavioral: Resonance breathing
Behavioral: Low demand cognitive task

First Posted Date: 2022-05-11

Last Posted Date: 2022-07-18

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 100

Registration Number: NCT05369169

Locations: 🇺🇸
Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Liver Cell Carcinoma
Carcinoma, Hepatocellular

Interventions: Drug: Tislelizumab

First Posted Date: 2022-05-09

Last Posted Date: 2023-05-12

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 35

Registration Number: NCT05366829

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

Phase 2

Recruiting

Conditions: Cancer of Rectum

Interventions: Drug: combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)

First Posted Date: 2022-05-03

Last Posted Date: 2023-09-21

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 38

Registration Number: NCT05358704

Locations: 🇺🇸
RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, Livingston, New Jersey, United States
🇺🇸
Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
RWJBarnabas Health - Community Medical Center, Toms River, New Jersey, United States

and more 2 locations

ATATcH Alternating Treatment Plans for Advanced Cancer

Phase 2

Recruiting

Conditions: Head and Neck Cancer
Lung Cancer

Interventions: Drug: 5Fluorouracil
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Carboplatin
Drug: Pembrolizumab

First Posted Date: 2022-05-03

Last Posted Date: 2024-04-10

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 150

Registration Number: NCT05358548

Locations: 🇺🇸
RWJBarnabas Health - Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸
RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 8 locations

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Phase 1

Not yet recruiting

Conditions: Lung Cancer Stage III

Interventions: Drug: AN0025

First Posted Date: 2022-05-03

Last Posted Date: 2023-12-13

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 24

Registration Number: NCT05358691

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet

Phase 3

Recruiting

Conditions: Radiation Therapy
Metastatic Cancer

Interventions: Combination Product: Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Other: Questionnaires

First Posted Date: 2022-04-28

Last Posted Date: 2024-11-29

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 156

Registration Number: NCT05351294

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
RWJBarnabas Health Jersey City Medical Center, Jersey City, New Jersey, United States
🇺🇸
RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey, United States

and more 2 locations

Values and Options in Cancer Care 2 (VOICE 2) A Randomized Pilot Study

Phase 2

Recruiting

Conditions: Communication, Multidisciplinary

Interventions: Behavioral: Interventional Survey

First Posted Date: 2022-04-28

Last Posted Date: 2023-08-04

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 40

Registration Number: NCT05352451

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey-University Hospital, New Brunswick, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy